Pfizer Expects $10-$15B From mRNA Vaccine Sales By 2030, Sees $17B Revenues Lost Due To Patent Expiry

At Pipeline Day, Pfizer Inc (NYSE: NYSE:PFE) forecasts annual revenue from its mRNA vaccine portfolio could reach $10-$15 billion by 2030.
Last month in its Q3 earnings release, Pfizer raised its forecast for 2022 sales of its COVID-19 vaccine by $2 billion to $34 billion.
After the successful COVID-19 vaccine, Pfizer and BioNTech SE (NASDAQ: BNTX) initiated a Phase 1 study to evaluate the safety, tolerability, and immunogenicity of a next-generation COVID-19 vaccine candidate also based on mRNA technology.
Related: After Famed COVID-19 Pill, Pfizer Inks Research Pact For Another Antiviral Candidate.
Pfizer also expects to lose $17 billion in annual sales between 2025-2030 due to the patent expirations, Chief Commercial Officer Angela Hwang said in an investor presentation.
Some flagship products to lose exclusivity by 2030 include Eliquis, Ibrance, Xeljanz, and Xtandi.
Pfizer’s revenue is expected to top $100 billion this year – more than double its pre-pandemic level, Reuters reported on solid growth from its COVID-19 vaccine and treatment Paxlovid.
Analysts expect COVID-19 vaccine revenues to drop sharply beginning in 2023 and see sales of Pfizer’s Comirnaty at around $6.7 billion in 2027.
Price Action: PFE shares are up 2.13% at $53.27 during the premarket session on the last check Tuesday.